undefined undefined
NaN.000
NaN.00%
Scheduling U.S. site initiation visits April and May 2024On track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 at New York City lead site and other leading U.S. sites mid-2024No change in
04-18 21:46
Immix Biopharma, Inc. (NASDAQ:IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its 12-month progress update including shareholder letter. "The
02-21 22:39
Gainers Virpax Pharmaceuticals (NASDAQ:VRPX) stock rose 57.8% to $0.38 during ...
2023-12-16 01:31
美股新股INHD上市首日飙升246%;东方甄选“小作文”事件持续发酵,高途“坐收渔利”,隔夜暴涨29%,周内累涨72%。详情>>
2023-12-15 19:59
100% (9/9) overall response rate and 67% (6/9) complete response rate (MRD 10-5) observed in heavily pre-treated patients with daratumumab relapsed/refractory AL Amyloidosis as of the September 20, 2023 data cutoff100%
2023-10-03 21:16
Roth MKM analyst Jonathan Aschoff reiterates Immix Biopharma (NASDAQ:IMMX) with a Buy and maintains $14 price target.
2023-08-14 22:11
What is the target price for Immix Biopharma (IMMX)?The latest price target for...
2023-08-14 22:10
September 15, 2022 – The biotechnology industry is a vast sector consisting of ...
2023-07-24 19:08
https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11685769
2023-06-27 17:39
Immix Biopharma Inc (NASDAQ: IMMX) announced early interim data from IMMINENT-01 Phase 1b/2a trial combining tissue-specific therapeutic IMX-110 with BeiGene Ltd (NYSE: BGNE) / Novartis AG'
2023-05-04 02:42